ACP
ALDX icon

Acuta Capital Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Acuta Capital Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500,000
Closed -$2M – 42
2021
Q4 		$2M Buy
+500,000
New +$3.81M 0.84% 29
2021
Q1 		– Sell
-192,500
Closed -$1.32M – 47
2020
Q4 		$1.32M Sell
192,500
-1,454,200
-88% -$10.2M 0.36% 40
2020
Q3 		$12.2M Buy
1,646,700
+756,700
+85% +$4.89M 3.31% 9
2020
Q2 		$3.71M Buy
+890,000
New +$3.25M 1.07% 31

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acuta Capital Partners's ALDX Position: Q1 2022 in Review

Acuta Capital Partners sold out of Aldeyra Therapeutics (ALDX) in Q1 2022, closing a stake of 500,000 shares — an estimated $2M sold.

Acuta Capital Partners first reported a position in ALDX in Q2 2020 and held it in 4 quarters. The position peaked at $12.2M in Q3 2020. 111 funds tracked by Wall St. Rank hold ALDX as of Q1 2022.

  • Acuta Capital Partners reported no remaining Aldeyra Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 500,000 Aldeyra Therapeutics shares in Q1 2022, an estimated $2M.
  • Acuta Capital Partners first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 4 quarters.
  • Acuta Capital Partners's Aldeyra Therapeutics position peaked at $12.2M in Q3 2020.
  • 111 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2022.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.